Eli Lilly & Co (LLY): Cost of Revenue

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2017-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$11.05B

Year ended 2025-12-31

$13.22B

Trailing 12 months to 2026-06-30

+18.6%

3-year compound annual growth

+15.0%

5-year compound annual growth

2016-12-31 Cost of Revenue (USD) 2025-12-31

Period ended	Cost of Revenue	Change YoY	Source filing
2025-12-31	$11.05B	+31.3%	2026-02-12, From 2025-01-01
2024-12-31	$8.42B	+18.9%	2026-02-12, From 2024-01-01
2023-12-31	$7.08B	+6.8%	2026-02-12, From 2023-01-01
2022-12-31	$6.63B	-9.3%	2025-02-19, From 2022-01-01
2021-12-31	$7.31B	+33.4%	2024-02-21, From 2021-01-01
2020-12-31	$5.48B	+16.1%	2023-02-22, From 2020-01-01
2019-12-31	$4.72B	+0.8%	2022-02-23, From 2019-01-01
2018-12-31	$4.68B	+5.3%	2021-02-17, From 2018-01-01
2017-12-31	$4.45B	n/c	2020-02-19, From 2017-01-01
2016-12-31	$5.71B	n/a	2019-02-19, From 2016-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cost of Revenue	Change YoY
Eli Lilly & Co (LLY)	2025-12-31	$11.05B	+31.3%
Merck & Co., Inc. (MRK)	2025-12-31	$16.38B	+7.8%
Pfizer Inc (PFE)	2025-12-31	$16.07B	-10.0%
AbbVie Inc. (ABBV)	2025-12-31	$18.20B	+7.7%
Bristol Myers Squibb Co (BMY)	2025-12-31	$13.94B	-0.2%
Johnson & Johnson (JNJ)	2025-12-28	$30.26B	+10.1%
Abbott Laboratories (ABT)	2025-12-31	$19.32B	+3.3%
Teva Pharmaceutical Industries Ltd (TEVA)	2025-12-31	$8.32B	-1.9%
Viatris Inc (VTRS)	2025-12-31	$9.29B	+1.9%

Compare LLY, MRK, PFE, ABBV side by side · Screen every company in Pharmaceutical Preparations ↗